Professor Sharon Peacock - CBE FMedSci | Website and Blog
14869
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-14869,bridge-core-2.5.3,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-23.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive

Slide Welcome to Professor
Sharon Peacock's Research Group
ABOUT US

Professor Sharon Peacock CBE FMedSci is a Professor of Public Health and Microbiology in the Department of Medicine, University of Cambridge, and Executive Director and Chair of the COVID-19 Genomics UK (COG-UK) consortium. She is a world authority on pathogen genomics, antibiotic resistance, and a range of specific infectious pathogens. This includes Staphylococcus aureus (including MRSA), and Burkholderia pseudomallei (the cause of the tropical infectious disease, melioidosis).  Professor Peacock is a non-executive director at Cambridge University Hospitals NHS Foundation Trust, and holds a secondment with Public Health England (PHE) as Director of Science (Pathogen Genomics).

Professor Peacock’s Lab work on three main themes: translating pathogen sequencing into clinical and public health microbiology; the evolution and transmission of bacterial and viral pathogens; and the biological basis of bacterial carriage and disease. Our emphasis is on work that leads to improved disease control through infection control intervention and therapeutics. All members of the Peacock group have been actively engaged in the response to COVID-19.

The transfer of skills and knowledge to others is central to our work and ethos. We support career development through skills-based, MSc and PhD, and short course training. This includes contributions to numerous short courses in the UK and globally.

OUR LAB

Our laboratories and offices in the Department of Medicine are based at the Cambridge Biomedical Campus. Our laboratory is located a short walk from a diagnostic microbiology laboratory that serves numerous hospitals in the region, and the acute care wards of the Cambridge University Hospitals. This co-location allows us to remain closely integrated and supports work on important questions that depend on access to clinical samples and patient data. We maintain pathogen sequencing capabilities on site, as well as an extensive collection of bacteria isolated from patients, livestock and the environment that are linked to epidemiological and whole genome sequence data.